{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106913","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.926352+00:00","generated_at":"2026-05-17T14:44:10.671007+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Climb Bio Q2 cash $187.4M, R&D $6.6M; budoprutug trials underway; new CMO","bullets":["Cash and marketable securities $187.4M as of June 30, 2025; cash runway expected through 2027.","R&D expenses $6.6M in Q2 2025 vs $1.0M in Q2 2024; no acquired IPR&D expense in 2025.","Budoprutug ITP and SLE trials dosing patients; pMN Phase 2 to initiate; SC formulation Phase 1 data expected H1 2026.","CLYM116 investor event September 2025 with preclinical data; IND/CTA for IgAN expected H2 2025.","Edgar D. Charles, M.D., MSc appointed CMO, joining from Bristol Myers Squibb in June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106913","json":"https://secwatch.observer/filing/0000950170-25-106913.json","markdown":"https://secwatch.observer/filing/0000950170-25-106913.md","text":"https://secwatch.observer/filing/0000950170-25-106913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/0000950170-25-106913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:44:10.671007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}